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Acetate dialysis (abst) 233, 806
Acetate-free bicarbonate dialysate (abst) 237
Acetate-free biofiltration (abst) 218, 230, 233, 501
Acid-base balance
ion H unit scale (abst) 236
pH changes, uremic neutrophils 690
relationship of EPO (abst) 804
Acquired cystic renal disease (abst) 198
Actin, PDGF in glomerulogenesis 390
Acute arterial occlusion in ARF (abst) 215
Acute pancreatitis, CAPD (abst) 1287
Acute pyelonephritis (abst) 1040, 1043
Acute renal failure
acute arterial occlusion (abst) 215
insulin-like growth factor-I (abst) 1048
ischemic, urodilatin, dopamine 1153
mild renal ischemia 610
nephrotic syndrome (abst) 495
percutaneous biopsy (abst) 495
thrombocytopenia (abst) 1044
Acyclovir, cytomegalovirus, allografts (abst) 235
Adenosine triphosphatase in medulla 1093
Adenylate cyclase activity, cytokines 559
ADP, mitochondria-transport ATPases (abst) 221
Adrenalectomy, lipocortin-l mRNA (abst) 800
Adriamycin
blunted volume expansion natriuresis (abst) 234
glomerulosclerosis, captopril (abst) 506
nephropathy (abst) 1283
nephrotic syndrome, antioxidants (abst) 507
Alanine cytoprotective action 775
Albumin
excretion, children (abst) 1044
excretion, glycosaminoglycans 285
GBM permeability 25
Alcoholism, GN, post-infectious (abst) 232
Aldosterone, target epithelia 250
Alfacalcidol, hyperparathyroidism (abst) 1035
Allografts.
acyclovir, cytomegalovirus (abst) 235
dysfunction, cytomegalovirus (abst) 222
dysfunction, Doppler (abst) 221}ILA sensitization (abst) 220
IL-2, TNF, neopterine, creatinine (abst) 231
rejection, immunopharmacology 38:S-182
rejection, T-cells (abst) 1047
renal artery stenosis, transplantation (abst) 1286




COL4A5 structure, diffuse leiomyomatosis 1178
collagen IV, GBM 179
collagen IV, V and VI 115
Aluminum
blood levels, hemoglobin (abst) 502
blood levels (abst) 204
bone disease, predialysis (abst) 212
bone disease, RF (abst) 213
renal osteodystrophy (abst) 498
Aluminum toxicity
calcium alginate, HD (abst) 1045
prurigo nodularis (abst) 1044
Amiloride, lithium reabsorption (abst) 1286
Ammonia, protein metabolism 595
Amylase isoenzymes, renal clearance (abst) 1286
Amyloidosis
dialysis-related 38:S-78
dialysis-related, protease inhibitors 915
dialysis-related, systemic (abst) 201
HD membrane, a-2M (abst) 1040





hemodialysis, angiodysplasia (abst) 228
hemodialysis, rHuEPO (abst) 501
multiple myeloma, ESRD (abst) 233
pathogenesis in CRF (abst) 796
predialysis CRF, rHuEPO (abst) 498
transplantation, enalapril (abst) 206
transplantation, EPO-deficiency (abst) 216
uremia, EPO 975
uremia, EPO, hypoxic vasodilation 975
uremia, rHuEPO 38:S-142
Angiodysplasia, HD, anemia (abst) 228
Angiotensin, blood pressure, CRF 46
Angiotensin converting enzyme (ACE) inhibition
BP control (abst) 220
bradykinin, Nephrology Forum 1020
calcium antagonists, renal mass, BP (abst) 211
decrease in proteinuria (abst) 1285
EPO concentrations (abst) 1030
hypoxemia-induced insufficiency (abst) 799
metabolic effects (abst) 1039
microalbuminuria (abst) 200
nephrotic proteinuria (abst) 213
renal disease, Nephrology Forum 463
Angiotensin II
endothelin secretion, MC 860
receptors in rat medulla 1372
stenotic kidney 417
Anisodamine, ARF (abst) 495
Anti-DNA antibodies, glomerular binding 1363
Anti-endothelial cell antibodies, SLE (abst) 1038
Anti-GBM glomerulonephritis
deoxyspergualin therapy (abst) 1034
glomerular fibrinolytic activity (abst) 1034
T-cells (abst) 1032
Anti-hypertensive drugs, renal effect 354
Anticardiolipin antibodies (abst) 233
Antilymphocyte globulins, transplantation 38:S- 188
Antioxidants, adriamycin, nephrotic syndrome (abst).... 507
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Aortocaval fistula, ANP, in dogs 867
Arginase, L-arginine metabolism, GN 1107
Arginine vasopressin, vascular smooth muscle cells
(abst), 799
Aromatic L-amino acid decarboxylase 617
Arterial occlusion, acute in ARF (abst) 215
Astragalus Propinquns Schichk (abst) 505
Atenolol, diabetic nephropathy, GFR (abst) 794
ATP turnover (abst) 221
Atrial natriuretic factor
down-regulation of salt excretion 673
Prazosin, natriuresis 433
receptors, responses in hypertrophy 75
Atrial natriuretic peptide (ANP)
aortocaval fistula dogs 867
displacement by urodilatin (abst) 234
receptor, dietary fatty acid 265
renal action 38:S-l27
severe hyponatremia (abst) 1031
Autoreactive kidney-infiltrating T-cell clones 851
Autosomal-dominant polycystic kidney disease
(ADPKD)
acute cerebrovascular attacks (abst) 225
blood pressure, kidney volume (abst) 211
diagnosis with DNA probes (abst) 207
gene testing (abst) 491
genetic clinical study (abst) 202
genetic counseling (abst) 207
genetic diagnosis (abst) 210
probability kidneys are different in 1199
tubular renin 364




Bacterial contamination, dialyzer membrane 61
Bartter's syndrome (abst) 1287
13 integrins, glomerular epithelial cells 1099
f32-microglobulin
elimination, HD (abst) 209
removal in hemodiafiltration (abst) 1045
turnover, dialysis 1434
Bezafibrate, lipoproteins, CRF, HD (abst) 199
Bicarbonate dialysis
acetate-free biofiltration (abst) 501
cardiac function and (abst) 233
pre-dialytic hypotension (abst) 230
vascular refilling (abst) 806
venous system hemodynamics 718
Bicarbonate diuresis (abst) 503
Biopsy
renal, detects CMV genome 1012
renal, diabetic nephropathy (abst) 229
renal percutaneous (abst) 494, 495
tubulointerstitial lesions (abst) 494
Blood pressure
ACE inhibitors (abst) 220
angiotensin, CRF 46
elevation, saline infusion (abst) 508
hemodialysis, CRF (abst) 215
systemic, DM, Nephrology Forum 1470
"white coat" hypertension (abst) 202
Blood transfusions, pretransplant (abst) 208
Bone disease
adynamic, dialysis 38:S-62
aluminum, advanced RF (abst) 213
aluminum (abst) 212, 498
aseptic necrosis (abst) 221
Bone marrow
hemopoietic progenitor, dialysis (abst) 502
rHuEPO, chronic insufficiency (abst) 206
Bone metabolism, renal insufficiency (abst) 499
Bone mineral density
dialysis (abst) 805
transplantation (abst) 211, 808, 1048
Bowman's capsule, leukocytes, anti-GBM disease
(abst) 1051
Bradykinin-mediated effects of ACE inhibition,
Nephrology Forum 1020
C4 null phenotype, mutations, gene deletions (abst) .... 1032
C4 RFLPs, membranous nephropathy 882
C9 deficiency and IgA nephropathy 1253
Calcineurin, cyclophilin-cyclosporine complex (abst) .... 802
Calcitriol
hyperparathyroidism, HD (abst) 1041
low-dose, dialysis 1191
non-calcemic vit D analogs 38:S-43
Calcium
intracellular, proximal tubules (abst) 797
ketodiet in osteodystrophy 1217
mass balance, calcium dialysate, HD (abst) 230
metabolism, nephrotic syndrome 335
metabolism, renal failure 38: S-37
renal lithiasis (abst) 204
Calcium alginate, aluminum toxicity, HD (abst) 1045
Calcium pump inhibitor, uremia 1328
Calcium renal stones (abst) 803
Calcium salts as phosphate binder, uremia 38:S-50
Calorie restriction and remnant kidney 710
Cancer, renal/pelvic (abst) 1042
CAPD
acute pancreatitis (abst) 1287
adequacy of 38:S-160
autoimmune hypothyroidism (abst) 198
complement system, children (abst) 797
fluid kinetics, hypo-osmotic solution (abst) 797
high molecular weight dialysate (abst) 503
IL-l receptor antagonist, CRF 1419
intraperitoneal neostigmine 1398
lipoprotein level 424
older patients at home (abst) 503
pentoneal defenses, CCPD 947
peritoneal function (abst) 205
peritoneal inflammation 735
peritonitis, fungal (abst) 200
peritonitis, prostaglandins (abst) 798
peritonitis, rates/risks 967
staphylococcus aureus, rHuEPO (abst) 204
urea kinetic model of evaluation (abst) 205
Captopril
adriamycin, glomerulosclerosis (abst) 506
diabetic nephropathy, albuminuria (abst) 794
nifedipine, renal insufficiency 452
renal artery stenosis (abst) 206, 1287
Cardiac hypertrophy in uremic rats 1079
Cardiopulmonary recirculation modeling 1450
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Carotid artery traction, natriuresis (abst) 234
CD4 monoclonal antibody therapy (abst) 1033
CD25 monoclonal antibody therapy (abst) 1033, 1046
254Ag monoclonal antibody (abst) 1036
Ceftizoxime, endotoxin influence (abst) 507
Cell electrolytes, osmolytes in outer medulla 843
Cell-type specific ganglioside of podocytes 624
Cellular metabolites, renal injury 38:S-109
Cerebrovascular attacks, ADPDK (abst) 225
Children
asymptomatic syndrome (abst) 492
complement system, CAPD (abst) 797
Dengue fever nephritis (abst) 493
glomerular disease (abst) 492
HBV glomerulonephritis (abst) 493
hemolytic uremic syndrome, IL-8 951
lead poisoning, renal function 1226
lupus nephritis (abst) 1043
nephrotic syndrome (abst) 492, 493, 1038
orthostatic proteinuria (abst) 493
peritoneal equilibration test 102
rhGH, calcium (abst) 1040
TNF, glomerular disease (abst) 492
transplantation 657, 1408
transplantation (abst) 802
uremia, growth hormone, Nephrology Forum 188
urinary albumin excretion (abst) 1044
Chinese herbal medicine (abst) 498, 504, 505, 510
Chondrocalcinosis, Bartter's syndrome (abst) 1287
Chromogranin, glomerular peripolar cells (abst) 1049
Chronic lymphocytic leukemia, GN 127
Chronic renal failure
angiotensin effect on BP 46
anti-platelet antibodies (abst) 497
bacterial enzyme products (abst) 497
bone disease (abst) 499
calcium pump inhibitor 1328
children, Nephrology Forum 188
Chinese herbal medicine (abst) 498, 504
hyperhomocysteinemia (abst) 229
IL-l receptor antagonist 1419
Liddle syndrome, nephrocalcinosis (abst) 233
membrane ionic permeability 300
02 consumption, PMNL 602
oxygen radicals, antioxidants (abst) 496
pathogenesis of anemia (abst) 796
predicting 960
prekallikrein-kallikrein system (abst) 496
PUPA, Oenothera Biennis L in CRF (abst) 498
rHuEPO, anemia, predialysis (abst) 498
serum hyaluronic acid (abst) 496
soluble TNF receptors 663
T-lymphocyte transformation, IL-2 (abst) 497
zinc, immunological functions (abst) 499
Chylomicron remnants in dialysis 1247
Cimetidine, creatinine, GFR (abst) 793
COL4A5 and Alport syndrome 83, 115, 1178, 1336
Collagen types, Alport syndrome 115, 179
Complement system
activation, OKT3, T-cells (abst) 796
CAPD, children (abst) 797
Continuous arteriovenous hemodiafiltration (CAVHD)
dialyzer geometry 448
role of convection (abst) 209
tobramycin clearance (abst) 209
Contrast medium, medullary sponge kidney (abst) 801
Converting enzyme inhibition, proteinuria (abst) 795
Cordyceps sinensis, ARF (abst) 495
Cortisol as a mineralocorticoid 1297
CR1 mRNA expression (abst) 228
Creatinine clearance (abst) 1043
Creatinine kinetics of evaluating CAPD (abst) 205
Crescentic glomerulonephritis (abst) 489
Crescentic nephritis (abst) 510
Cryoglobulinemia, hepatitis virus C (abst) 803
Cuprophane membranes, dialyzer geometry 442
Cyclic AMP
G-protein stimulation, Na/H exchange 11
ionic permeability, CRF 300
Cyclic peritoneal dialysis, CAPD 947
Cyclophilin-cyclosporine complex (abst) 802
Cyclophosphamide trials, idiopathic MGN (abst) 1032
Cyclosporin A
diltiazem, transplantation (abst) 1047
luteinizing hormone secretion (abst) 802
proteinuria, adriamycin nephropathy (abst) 1283
Cyclosporine
chronic liver disease (abst) 226
corticoid-resistant nephrotic syndrome (abst) 802
distal urinary acidification (abst) 225
gingival hyperplasia (abst) 223
glomerular thrombosis (abst) 1052
graft survival, HLA typing 38:S-172
HLA sensitization, allografts (abst) 220
liver transplantation, ARF (abst) 227
nephrotoxicity 1
nephrotoxicity, P-170 glycoprotein (abst) 223
proximal tubules (abst) 221
toxicity, endothelin antagonism 770
toxicity (abst) 236
transplantation (abst) 205, 216, 226
Cyprofloxacin, acute pyelonephritis (abst) 1040
Cyst epithelial cells, NaC1 transport 308
Cystic renal disease, acquired (abst) 198
Cystitis, corinebacterium D2 group (abst) 226
Cytokines
adenylate cyclase activity 559
glomerular cell production (abst) 1037
IgA nephropathy 341
Cytomegalovirus
allografts, acyclovir (abst) 235
DNA, IgA nephropathy, hematuria (abst) 488
genome, renal biopsy detection 1012
infection, allograft dysfunction (abst) 222
transplantation (abst) 207, 216
DDAVP, hemodynamics, renin secretion (abst) 793
ddl as HIV treatment (abst) 234
DEAE-dextran, glomerular selectivity (abst) 1049
Dengue fever nephritis, children (abst) 493
Deoxyspergualin, anti-GBM GN (abst) 1034
Dextran sulfate (abst) 1049
Diabetes
dialysis, bone histomorphometry (abst) 214
transplantation 38:S-193
Diabetes, non-insulin dependent
glomerular volume (abst) 1053
glycemic control, nephropathy 167
Diabetes insipidus
hydronephrosis, UT traumatic rupture (abst) 801
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Diabetes mellitus
systemic BP, Nephrology Forum 1470
Diabetic nephropathy
captopril, atenolol, GFR (abst) 794
Chinese herbal medicine (abst) 504
dyslipoproteinemia 1381
enalapril, diet, microalbuminuria (abst) 208
fibroblast Na/H antiport activity 1184
glycemic control, NIDDM 167
hyperinsulinemia, glomerular hemodynamics 1160
prevention with glycosaminoglycans 285
renal arteriosclerosis (abst) 1052
renal biopsy (abst) 229
thromboxane 937
Dialysis
adequacy of, critical analysis 540
adynamic bone disease 38:S-62
amyloidosis and 38:S-78
blood serotonin levels (abst) 1045
bone mineral density (abst) 805
clearing chylomicron remnants 1247
dry weight measurement (abst) 796
EPO, cytotoxic antibodies (abst) 218
hepatitis C virus (abst) 204
lipids, nutritional status (abst) 200
polymorphonuclear cells, infection 38:S-91
protease inhibitors, amyloidosis 915
systemic amyloidosis (abst) 201





permeability to pyrogens 61
reused, anaphylactoid reactions 1232
Dietary fatty acid, ANP receptor 265
Dietary protein
restriction, murine PKD 837
vasopressin, hydration 1207
Dietary salt
endothelin vasoconstrictive effect (abst) 508
hypertension (abst) 1038
Digital intra-venous arteriography substraction (abst).... 214
Diltiazem, transplantation, cyclosporin A (abst) 1047
Dipyridamole trials, idiopathic MGN (abst) 1032
Diuretic effect in outer medulla 843
Dobutamine, renal metabolism, endotoxemia (abst) 796
Donor organs
HLA typing (abst) 224, 809
MLC-testing (abst) 807
procurement (abst) 227
Dopamine, urodilatin, ischemic ARF 1153
Dopexamine, renal metabolism, endotoxemia (abst) 796
Doppler
allograft dysfunction evaluation (abst) 221
renal artery stenosis, transplantation (abst) 201
Dry weight measurement, post-dialysis (abst) 796
Dyslipoproteinemia, diabetic renal failure 1381
Eicosanoids
glomerular hemodynamics, IgA nephropathy 106
superoxides, cell injury 69
Electrolytes, cell
osmolytes, outer medulla 843
Enalapril
anemia, transplantation (abst) 206
microalbuminuria, diet, IDDM (abst) 208
End-stage renal disease
EPO, anemia, multiple myeloma (abst) 233
HD, IgE associated (abst) 230
hemodialysis, RBC (abst) 496
prognosis with spinal cord injury (abst) 1031
treatment (abst) 802, 1043
tumor necrosis factor-a (abst) 497
USRDS mortality tables 991
Endoglin, differentiation marker, macrophages (abst)... 1036
Endothelial cells, allo specific antibodies (abst) 1284
Endothelial-derived relaxing factor, obstruction 400
Endothelin
antagonism, cyclosporine toxicity 770
blood volume (abst) 508
glomerular mesangial cells (abst) 509
renal artery obstruction 632
vasoconstriction, dietary salt (abst) 508
Endothelin- 1
Na/H, Na/HCO3 18
secretion, angiotensin II, MC 860
Endothelium, renal artery obstruction 632
Endotoxemia, interstitial nephropathy (abst) 494
Endotoxin
low-dose, preeclampsia (abst) 1283
metabolic of ceftizoxime (abst) 507
Epidermal growth factor, MC production (abst) 1036
Epithelial cells
adhesion, f integrins 1099
aldosterone action 250
culture, cell lines (abst) 236
membrane fluidity, transport 825
Erythrocytosis post-transplant (abst) 219
Erythropoietin
ACE inhibitors (abst) 1030
anemia, ESRD, multiple myeloma (abst) 233
anemia, transplantation (abst) 216
arterial pressure (abst) 215
cardiac effects (abst) 1041
cell culture production (abst) 510
glomerular hemostasis (abst) 804
HD, CD34+ cells (abst) 216
HD, hemoglobin, hematocrit (abst) 237
hippuric acid (abst) 804
hypobaric exposure (abst) 804
02, hypoxic vasodilation 975
relation to acidosis (abst) 804
subcutaneous dosage (abst) 805
uremia 407
uremia (abst) 1031
Essential fatty acids, graft survival (abst) 1041
Essential hypertension
association with obesity (abst) 208
insulin resistance (abst) 225
metabolic tolerance to medical treatment (abst) 225
Excretory urogram, medullary sponge kidneys (abst) ... . 801
Expert systems diagnose glomerular disease (abst) 1031
Extraglomerular vascular immune deposits, IgA GN.... 1444
Fatty acids
deficiency, graft survival (abst) 1041
dietary, ANP receptor 265
Felodipine
during dopamine blockade (abst) 795
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proximal tubule effect (abst) 1031
Fenoterol, hyperkalemia treatment (abst) 198
Fibrillary glomerulonephritis 1401
Fibroblast Na/H antiport activity 1184
Fibronectin
mRNA splice variants (abst) 1037
synthesis, TGF-/31, human MC (abst) 1032
Flow cytometry, renal tubular cells 997
Focal segmental glomerulosclerosis (abst) 489, 799
Fungal peritonitis in CAPD (abst) 200
G-protein stimulation, cyclic AMP 11
Ganoderma capense (abst) 504
Gastrointestinal bleeding, periodic HD (abst) 201
Gentamicin toxicity (abst) 232, 495
Gingival hyperplasia and cyclosporine (abst) 223
Globotriaosylceramide, TNF, IL-i (abst) 1286
Glomerular basement membrane
anionic charge concentration (abst) 1050
defect in Alport 179
permeability 25
Glomerular cell types in rat kidney (abst) 1051
Glomerular disease
children (abst) 492
diagnosis, applied machine learning (abst) 1031
glucocorticoids 981
immunologically mediated 38:S-123
Glomerular fibrinolytic activity, anti-GBM GN (abst)... 1034
Glomerular filtration rate
creatinine, cimetidine (abst) 793
glycosilation products 875
measurement, 99mTcDTPA, inulin 174
modified plasma clearance 1006




Glomerular hypertrophy, post-uninephrectomy 136
Glomerular peripolar cells (abst) 1049
Glomerular thrombosis, cyclosporine (abst) 1052
Glomerulogenesis, actin and PDGF 390
Glomerulonephritis
CLL, related lymphomas 127
complicated with hemoptysis (abst) 491
crescentic (abst) 489
fibrillary 1401
glomerular anionic sites (abst) 491
IgA, eicosanoid synthesis 106
IgA, mesangial proliferative (abst) 223
IgA deficiency, mesangial (abst) 219
incidence, Spain (abst) 219
L-arginine metabolism, arginase 1107
leukotriene antagonists 38:S-l01
MA histological analysis (abst) 199
membrane attack complex (abst) 507
mesangial, IL-i (abst) 507
mesangial, IL-6 (abst) 800
plasmin protease system 1462
post-infectious, alcoholism (abst) 232
proliferative lupus, cyclophosphamide (abst) 208
T-cells, lymphokines, anti-GBM ON (abst) 1032
Glomerulopathy
antiphospholipid antibodies (abst) 225
thromboxane, diabetes 937
Glomerulosclerosis
adriamycin, captopril (abst) 506
focal segmental (abst) 489
IL-l (abst) 1051
Glomerulus
anti-DNA antibody binding 1363





homeostasis, Nephrology Forum 1266
MC proliferation, TGF-/3 647
transport, insulin-responsive 1086
Glycine metabolism, proximal tubular (abst) 1049
Glycine protective action 41, 775
Glycosaminoglycans prevent nephropathy 285
Glycosilation products, glomerular hyperfiltration 875
Grafts
determining function (abst) 203
embolization of with alcohol (abst) 202
rejection, natural killer cells (abst) 224
rejection, steroid/OKT3 therapy (abst) 223
survival, cyclosporine, HLA typing 38:S-l72
survival, essential fatty acids (abst) 1041
Growth hormone
calcium regulation, children (abst) 1040
Growth hormone, uremic children, Nephrology Forum .. 188
Guanidines, assay in plasma, urine (abst) 807
H-K-ATPase in renal medulla 1093
5-hydroxytryptamine receptors, noradrenaline (abst).... 1285
1 13-hydroxysteroid dehydrogenase, mammalian
nephron 56
Hantavirus nephropathy (abst) 1285
Hematuria, asymptomatic, children (abst) 492
Hemodiafiltration (abst) 1044, 1045
Hemodialysis
AgHBs, dialysis ultrafiltrate (abst) 232
amyloidosis, a-2m (abst) 1040
anaphylactoid reactions (abst) 218
angiodysplasia, anemia (abst) 228
antioxidant capacity, uremic erythrocytes (abst) 222
antiphospholipid antibodies, CRF (abst) 211
f32-microglobulin elimination (abst) 209
f32-microglobulin turnover 1434
blood rheology (abst) 1046
bone marrow hemopoietic progenitor (abst) 502
calcitriol, hyperparathyroidism 1191
calcium alginate, aluminum hydroxide (abst) 1045
calcium balance, calcium dialysate (abst) 230
cardiopulmonary recirculation modeling 1450
circadian BP rhythm, CRF (abst) 215
compared with hemodiafiltration (abst) 1044
control of hyperphosphatemia (abst) 807
deformability of RBC (abst) 501
dialysates, ventricular function (abst) 233
dialyzer geometry 442, 448
echocardiographic studies (abst) 216
elevated serum aluminum (abst) 502
endotoxic antibody (abst) 501
Europe and U.S 38:S-l6
gastrointestinal bleeding (abst) 201
hemodynamics, hemorrheology (abst) 500
hemodynamics, venous system 718
hepatitis B vaccination (abst) 212
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hepatitis C virus (abst) 205, 207, 208, 209, 218
high-efficiency (abst) 500
high-flux dialysis, polysulfone membrane (abst) 500
hollow-fiber, hemostasis (abst) 235
hollow-fiber, hemostatic disturbances (abst) 807
HTLV- 1 antibodies (abst) 238
hypercalcemia (abst) 806
hypotension, nitric oxide role 38:S-96
IL-i, TNF 38:S-68
IL-I receptor antagonist, CRF 1419
IL-2 generation (abst) 199
IL-6 production 320
Legionella outbreak (abst) 219
lipoprotein level 424
lipoproteins, CRF, bezafibrate (abst) 199
lipoproteins, CRF (abst) 200
low dialysate flow rate (abst) 500
low molecular weight heparin (abst) 217, 235
measuring mass transfer (abst) 805
nutritional assessment (abst) 201
parathyroid hormone, erythropoiesis (abst) 502
post-catheterism vein stenosis (abst) 235
prevention of hepatitis B (abst) 501
race, diabetes and death risk 38:S-22
RBC, ESRD (abst) 496
rHuEPO, anemia (abst) 501
rHuEPO, heme metabolism (abst) 215
rHuEPO, hemorrheological parameters (abst) 214
single-needle, citrate anticoagulation (abst) 807
technetium-labeled heparin (abst) 231
urea distribution volume (abst) 217
urea kinetic model (abst) 500
vascular access (abst) 214, 232, 233
vascular refilling during 1425
Hemodynamic dysfunction in DM, Nephrology Forum.. 1470
Hemolytic uremic syndrome
IL-i, TNF (abst) 1286
IL-8, neutrophils, children 951
Henoch-Schonlein purpura (abst) 490
Heparin
glomerular proteinuria (abst) 1050
low molecular weight, HD (abst) 217, 235
technetium-labeled, HD (abst) 231
Hepatitis B
chronic, glomerular disease (abst) 229
vaccination, HD (abst) 212
Hepatitis B virus
glomerulonephritis, children (abst) 493
pathogenesis (abst) 490
Hepatitis C virus
antibody, home HD (abst) 207
cryoglobulinemia type II (abst) 803
dialysis (abst) 204
hemodialysis (abst) 205, 208, 209, 218
transplantation (abst) 226, 227
Herbal medicine (abst) 498, 504, 505, 510
Heymann's nephritis (abst) 1034, 1051
Hippuric acid, EPO response (abst) 804
HIV infection
ddl treatment (abst) 234
hemodialysis (abst) 238
Ig binding to IgAN collagens 374
renal disease (abst) 230
HLA typing
allocating kidneys and (abst) 1285
donor kidneys (abst) 809
graft survival, cyclosporine 38:S-172
lymphocytes, cadaver donors (abst) 224
sensitization, potential recipients 38: S-176
Hollow-fiber membranes
hemostatic disturbances (abst) 235, 807
reused, anaphylactoid reactions 1232
HSP7O mRNA transcription, regulation of 775
Hyaluronic acid, serum, CRF (abst) 496
Hypercalcemia
chronic hemodialysis (abst) 806
transplantation (abst) 1048
Hypercalciuria
idiopathic, renal lithiasis (abst) 202
insulin resistance, hypertension (abst) 225
prostaglandins (abst) 212
Hypercapnia, chronic (abst) 503
Hypercholesterolemia (abst) 506
Hyperhomocysteinemia in CRF (abst) 229
Hyperinsulinemia, glomerular hemodynamics 1160
Hyperkalemia, fenoterol treatment (abst) 198
Hyperlipidemia




calcitriol, hemodialysis (abst) 1041
calcitriol, non-calcemic vit D analogs 38:S-43
hemodialysis, alfacalcidrol (abst) 1035
hemodialysis, tumoral calcinosis (abst) 806
low calcium dialysate (abst) 1041
MRI, subtraction gammagraphy (abst) 221
02, CRF, PMNL 602
secondary uremic (abst) 208
transplantation (abst) 211, 806, 808, 1048
treatment, renal function (abst) 204
Hyperphosphatemia
calcium acetate as phosphate binder (abst) 807
chronic respiratory alkalosis 727
Hypertension
ACTH, sodium chloride (abst) 1039
dietary NaCI (abst) 1038
exercise, pH recovery (abst) 1038
insulin resistance, hypercalciuria (abst) 225
insulin resistance, vascular risk factors (abst) 224
monitoring "white coat" (abst) 202
NaIH exchange 1355
pregnancy, altered excretion rates (abst) 1039
pregnancy, proteinuria (abst) 1038
Hypertransaminasemia, hepatitis C virus, HD (abst) 208
Hypobaric exposure, EPO response (abst) 804
Hypocalcemia, chronic respiratory alkalosis 727
Hypocalciuria in kidney injury (abst) 216
Hypomagnesemia, Bartter's syndrome (abst) 1287
Hyponatremia, ANP (abst) 1031
Hypophosphatemia, post-transplant (abst) 803
Hypothyroidism, autoimmune in CAPD (abst) 198
Hypoxia
glycine protection mechanism 41
protein kinase C, cell differentiation 1145
ICAM-l expression, effect on phagocytes (abst) 1037
Idiopathic membranous glomerulonephritis
cyclophosphamide, warfarin, dipyridamole (abst) .... 1032
predicting CRF 960
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Idiopathic membranous nephropathy
C4 RFLPs 882
early stage (abst) 488
IgA deficiency, mesangial GN (abst) 219
IgA glomerulonephritis
urinary platelet factor 4 (abst) 1051
vascular immune deposits 1444
IgA nephritis (abst) 238
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